Agios Pharmaceuticals Inc 2026 SR
The report highlights Agios Pharmaceuticals' sustainability and ESG initiatives for the fiscal year 2025. Key achievements include the historic U.S. FDA approval of AQVESME™ (mitapivat) for anemia in adults with alpha- or beta-thalassemia, alongside expanding global reach in Saudi Arabia and the United Arab Emirates. The company advanced its multicultural engagement strategy to improve healthcare access and address language barriers for thalassemia patients. Agios also invested over $1.0 million in both medical education and patient advocacy sponsorships, while successfully demonstrating base-metal catalyzed flow hydrogenation at commercial scale to reduce manufacturing waste and emissions.
Company: Agios Pharmaceuticals Inc
Sector: Health Care
Country: United States
Year: 2026
Type: SR
Pages: 42
Agios Pharmaceuticals Inc
Environmental, Social, And Governance Report
The report highlights Agios Pharmaceuticals' sustainability and ESG initiatives for the fiscal year 2025. Key achievements include the historic U.S. FDA approval of AQVESME™ (mitapivat) for anemia in adults with alpha- or beta-thalassemia, alongside expanding global reach in Saudi Arabia and the United Arab Emirates. The company advanced its multicultural engagement strategy to improve healthcare access and address language barriers for thalassemia patients. Agios also invested over $1.0 million in both medical education and patient advocacy sponsorships, while successfully demonstrating base-metal catalyzed flow hydrogenation at commercial scale to reduce manufacturing waste and emissions.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2026
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities